An Overview of Dr. David Samadi’s Interview on His Life and Career

David Samadi is a globally recognized medical expert. He is the Robotic Surgery chief at the Lenox Hospital, New York, and the current chairman of Urology. The talented medical expert has managed to operate on several patients spread out in more than 40 countries. He is renowned for his use of sophisticated surgical robotics to effectively treat patients suffering from prostate cancer. Dr. Samadi recently opened up about his life and career in an interview.

How Did He Start Out and His Ways of Making Money?

Dr. David Samadi desired to become a doctor who would be helping people. He specialized in the area of prostate treatments and was fascinated with the fresh developments in the sector of robotic surgeries. Dr. Samadi revealed that he makes his money from helping men suffering from prostate cancer access treatment. He has come up with a unique treatment method of using a robotic method that is less invasive when compared to the traditional surgical procedures. This unique method also allows his patients to live cancer free. It took several years for Dr. Samadi to make even in his practice. His unique knowledge of using robots in the theatre made his career explode in the United States.

Marketing Strategy

Dr. Samadi revealed that he relies majorly on referrals to generate more business for his practice. The doctor also takes pride in ensuring that he is easily accessible for his patients. This has made his patients appreciate and completely trust him. His main aim is to always bring about commendable results after every surgery. Dr. Samadi terms the provision of quality services as the main reason behind his ever-expanding practice.

Traits that Make You Successful and Future Aspirations

Dr. Samadi stated that he likes to stick to schedules as establishing a routine to follow always make him more efficient. He also stated that he treats his staff just like he would his family members. He bonds with them and gets to know them better as he believes that surrounding himself with good people guarantees him of success.

About Dr. David Samadi

Dr. David Samadi was born in Iran but grew up in Persia. The Iranian Revolution forced Samadi and his brother to go to Belgium and figured out life on their own. David had a strong drive and ambition to assist people in fighting cancer, which became his calling after witnessing a prostate cancer process. He holds a Biochemistry degree from the Stony Brook University and went for his postgraduate studies at the Albert Einstein College of Medicine and Montefiore Medical Center.

Dr. Clay Siegall Talks About DNA Sequencing And Genetic Testing In Cancer

Cancer is a threat to the human life. This is because it has become of the leading causes of endless deaths and disabilities. Cancer is a collective term for numerous diseases, which differ in severity from one person to another. These differences are influenced by genetics, hormones and other biologically- related factors. The most notorious cancer in women and men is breast cancer and prostate cancer respectively. Recently, Dr. Clay Siegall, an expert in the field of cancer therapy, discussed the advances that have been made in the field and their benefits. It has been known that human genes, which have unique DNA codes and sequence, predispose them to the development of specific diseases like cancer.

Genetic testing, which involves the study of DNA code and sequence in the diagnosis and treatment of diseases like cancer, has helped physicians to make faster and accurate diagnoses. This way, they have been able to develop targeted treatment for individual patients. This process has facilitated the quick diagnosis of prostate cancer, which for many years relied on a slower process of blood work, biopsies, and ultrasounds. Clay said that the success in genome sequencing has enabled a Dutch hospital to develop an innovative method of diagnosing prostate cancer within two weeks. With such prompt diagnosis, patients are able to start immediate treatment.

About Clay Siegall

Dr. Clay Siegall is the co-founder and CEO of Seattle Genetics, a Seattle-based biotech company that focuses on the development of targeted cancer therapies. Clay has relied on extensive research, scientific innovation and drug development practices to build Seattle Genetics from scratch. Today, the company is an authority in the development of antibody-drug conjugates (ADCs). Its first FDA-approved drug is ADCETRIS. They are also developing a pipeline of over 20 drugs. Clay has entered into strategic partnerships with leading pharmaceutical companies.

Clay Siegall was inspired to venture into the field of cancer therapy after watching a close family member suffer from the severe disease. He studied zoology at the University of Maryland. Later he enrolled in George Washington University where he attained a PhD in Genetics. Previously, the successful scientist worked for various pharmaceutical companies, including the National Cancer Institute, Pharmaceutical Research Institute and Bristol-Myers Squibb. He has also held top leadership positions at Ultragenyx Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals.